XTX Topco Ltd decreased its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 67.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,284 shares of the biotechnology company's stock after selling 4,671 shares during the quarter. XTX Topco Ltd's holdings in Biogen were worth $349,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in the company. Inspire Trust Co. N.A. boosted its position in Biogen by 58.5% during the third quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company's stock worth $2,113,000 after purchasing an additional 4,025 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Biogen by 0.3% in the 4th quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company's stock worth $6,646,000 after buying an additional 111 shares during the period. Amundi grew its stake in Biogen by 35.6% in the 4th quarter. Amundi now owns 1,216,990 shares of the biotechnology company's stock valued at $183,461,000 after buying an additional 319,478 shares in the last quarter. Centre Asset Management LLC raised its holdings in Biogen by 7.7% during the 4th quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company's stock valued at $7,880,000 after acquiring an additional 3,698 shares during the period. Finally, Integrated Quantitative Investments LLC bought a new position in shares of Biogen in the fourth quarter worth $407,000. Hedge funds and other institutional investors own 87.93% of the company's stock.
Insider Buying and Selling at Biogen
In other news, Director Stephen A. Sherwin sold 8,760 shares of the company's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the sale, the director now directly owns 11,318 shares in the company, valued at $1,697,926.36. This represents a 43.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.
Biogen Stock Performance
Shares of BIIB stock traded down $0.67 during trading hours on Friday, reaching $118.84. The company had a trading volume of 1,538,299 shares, compared to its average volume of 1,350,289. Biogen Inc. has a one year low of $110.04 and a one year high of $238.00. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. The business has a fifty day moving average price of $132.47 and a 200-day moving average price of $149.14. The firm has a market cap of $17.40 billion, a PE ratio of 10.62, a price-to-earnings-growth ratio of 1.51 and a beta of 0.06.
Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, beating analysts' consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. Sell-side analysts predict that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
BIIB has been the topic of a number of analyst reports. Truist Financial decreased their price objective on Biogen from $220.00 to $210.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. The Goldman Sachs Group cut their price objective on shares of Biogen from $219.00 to $197.00 and set a "buy" rating for the company in a research report on Wednesday. Royal Bank of Canada boosted their price objective on shares of Biogen from $221.00 to $225.00 and gave the company an "outperform" rating in a research note on Tuesday, April 22nd. Canaccord Genuity Group lowered their target price on shares of Biogen from $298.00 to $265.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Finally, Scotiabank decreased their price target on shares of Biogen from $244.00 to $224.00 and set a "sector outperform" rating on the stock in a report on Thursday, February 13th. Eighteen analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $211.37.
Read Our Latest Analysis on BIIB
About Biogen
(
Free Report)
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
See Also
Before you consider Biogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.
While Biogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
